• Aude Guillemin, Benoît Rousseau, Cindy Neuzillet, Charlotte Joly, Helene Boussion, Philippe Grimbert, Philippe Compagnon, Christophe Duvoux, and Christophe Tournigand.
• Assistance publique-Hôpitaux de Paris, hôpital Henri-Mondor, oncologie médicale, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94010 Créteil, France.
• Bull Cancer. 2017 Mar 1; 104 (3): 245-257.

AbstractThe risk of cancer after solid organ transplantation is increased by 2.6 compared to overall population. Cancer is currently the third leading cause of death in solid organ transplanted patients, making screening and early management of de novo cancers a major challenge. This increased risk of cancer in this population results from the combination of known environmental risk factors of cancer, comorbidities of transplanted patients, and exposure to chronic immunosuppression. The prognosis of cancer in these patients seems poorer as compared to other cancer patients owing to their comorbidities, the immunosuppression and patient's poorer tolerance to oncologic treatment. Moreover, interactions between immunosuppressive agents and antitumor therapies must be taken into account in the therapeutic strategy. Better knowledge of the specificities of solid organ transplanted patients with de novo cancer is required to improve cancer care in this patient population. This article aims to review the current data available on de novo cancers in solid organ transplanted patients, with a focus on epidemiology, risks factors of de novo cancers, impact of immunosuppressive drugs and oncologic prognosis.Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

31 keywords...

hide…